A new HIV prevention drug, lenacapavir, will be made affordable for the world's poorest by late 2025.

A new long-acting HIV prevention drug, lenacapavir, could reach the world's poorest countries by late 2025 or early 2026. Already approved for treating multi-drug resistant HIV, the drug shows high effectiveness in preventing infection. The Global Fund, PEPFAR, and philanthropic foundations are partnering to ensure affordable access. Gilead Sciences signed deals with six generic drugmakers to produce and sell the drug at lower prices in 120 low and middle-income countries, pending regulatory approvals.

3 months ago
18 Articles